Picture of Hookipa Pharma logo

HOOK — Hookipa Pharma News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapTurnaround

Hookipa Pharma Inc Expected To Post A Loss Of $1.25 A Share: Earnings Preview

* HOOKIPA Pharma Inc  HOOK.OQ   HOOK.O  is expected to show
a rise
in quarterly revenue when it reports  results on August 8
(estimated) for the period ending June 30 2024
    * The New York City-based  company is expected to report a
164.7% increase in revenue to $7.091 million from $2.68 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for HOOKIPA Pharma Inc is
for a
loss of $1.25 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for HOOKIPA
Pharma
Inc is $45.00​, above​ its last closing price of $4.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.07       -1.02      1.10      Beat    207.3
 Jan. 1 0001   -1.96       -1.93      -2.20     Missed  -14
 Sep. 30 2023  -2.31       -2.10      -1.70     Beat    19​
 Jun. 30 2023  -1.86       -2.09      -2.20     Missed  -5.3
 ​​Jan.        -2.23       -2.26      -2.70     Missed  -19.5
 1 0001                                                 
 Jan. 1 0001   -1.78       -2.15      -1.70     Beat    20.9​
 Jan. 1 0001   -2.87       -2.82      -2.50     Beat    11.2
 Jun. 30 2022  -3.58       -3.60      -2.30     Beat    36.1
 This summary was machine generated August 6 at 15:24 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Hookipa Pharma

See all news